Adverse event detection in drug development: recommendations and obligations beyond phase 3

Area of Science:

• Pharmacovigilance
• Drug Safety
• Clinical Research

Background:

• Premarketing drug trials often involve limited participant numbers (500-3000) and short durations.
• These studies are insufficient for detecting rare adverse events or those with long latency periods.

Purpose of the Study:

• To review existing systems for postmarketing adverse event assessment.
• To highlight the necessity of postmarketing surveillance for comprehensive drug safety evaluation.

Main Methods:

• Review of spontaneous reporting systems.
• Analysis of computerized claims and medical record databases.
• Evaluation of formal postmarketing studies.

Main Results:

• Premarketing studies effectively identify efficacy and common adverse events.
• Existing postmarketing surveillance systems have distinct strengths and limitations.
• Current methods require enhancement for robust rare adverse event detection.

Conclusions:

• Postmarketing surveillance is indispensable for understanding the full benefit-risk balance of drugs.
• Further research is needed in analyzing spontaneous reports and automated databases.
• Improved designs for ad hoc and economically feasible large randomized studies are essential.